HIChol - Translational network for Hereditary Intrahepatic Cholestasis
Defective bile formation is referred to as cholestasis and can be caused by mutations in genes important for bile formation in the liver. Cholestasis as result of genetic variants is referred to as hereditary intrahepatic cholestasis and comprises a heterogeneous group of rare disorders characterized by defective bile formation and progressive liver disease often necessitating liver transplantation. The incidence of these disorders is estimated at 1:50.000, however, they account for 10-15% of neonatal cholestasis.
The clinical presentation is highly variable consequently to the different genes and mutation subtypes involved. A subgroup of these patients has an increased risk for liver cancer, however, the frequency and the underlying mechanism of this complication are unknown.
Aim of this translational network is the characterization of the genetic defects in patients with severe intrahepatic cholestasis as well as the analysis of the biological consequences of novel mutations. This will be addressed by in silico modeling, the use of induced pluripotent stem cell-derived liver cells, and biopsy-derived liver organoids. Thus, consequences of mutations on one or more genes on the function of the mutated proteins, on bile formation and on adaptive mechanisms will be studied and may help to identify future therapeutic targets. The network includes a clinical registry establishing genotype-phenotype relationships.
Results will not only provide a better understanding of this rare disease group but also generate clinical evidence, which will affect diagnosis, surveillance and treatment of these rare disorders in the future.Projects
- Next Generation Sequencing platform to detect variants underlying hereditary intrahepatic cholestasis: Prof. Dr. med. Verena Keitel-Anselmino and Dr. rer. nat. Carola Dröge, Heinrich-Heine-University Düsseldorf; Dr. med. Eva-Doreen Pfister and Dr. rer. nat. Amelie Stalke, Hannover Medical School (MHH).
- In silico prediction and in vitro confirmation of consequences of cholestasis-associated mutations: Prof. Dr. med. Dieter Häussinger and Prof. Dr. rer. nat. Holger Gohlke, Heinrich-Heine-University Düsseldorf.
- iPSC-based hepatic models and CRISPR/Cas engineered controls: Prof. Dr. med. Tobias Cantz, Hannover Medical School (MHH).
- Patient-specific 3D liver organoids to dissect pathomechanisms underlying hereditary intrahepatic cholestasis: Prof. Dr. (PhD) Jay Gopalakrishnan, Heinrich-Heine-University Düsseldorf.
- Genotype phenotype registry for hereditary intrahepatic cholestasis – HIChol Registry: Prof. Dr. med. Verena Keitel-Anselmino, Heinrich-Heine-University Düsseldorf and Prof. Dr. med. Ulrich Baumann, Hannover Medical School (MHH).
Prof. Dr. med. Verena Keitel-Anselmino
University Hospital Düsseldorf
Gastroenterology, Hepatology and Infectious Diseases
Tel: +49 211 8118268